Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma
Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma
复制标题
前列腺特异性膜抗原：骨肉瘤新的潜在预后标志物
DOI：
10.1007/s12032-011-0089-4
复制
发表时间：
2012-09-01
期刊：
影响因子：
3.4
通讯作者：
Wang, Lian-Tang
中科院分区：
文献类型：
--
作者：
Zeng, Chao;Ke, Zun-Fu;Wang, Lian-Tang
以往的研究表明，前列腺特异性膜抗原（PSMA）的表达仅限于肿瘤相关新生血管的内皮细胞。但PSMA在骨肉瘤中的表达及其临床意义尚不清楚。免疫组化及量子点探针检测结果显示，46.7%（21/45）的骨肉瘤中PSMA呈阳性表达，而骨纤维异常增殖症中未见PSMA表达。CD 34染色证实PSMA的表达和定位。更重要的是，PSMA的表达与肿瘤大小、肺转移和较差的生存率相关（PSMA阴性组的生存率为63.2%，PSMA阳性组为36.6%）。因此，PSMA可作为骨肉瘤患者的独立预后标志物，肿瘤相关新生血管中的PSMA染色可能是骨肉瘤抗血管生成治疗的潜在靶点。
Previous studies have demonstrated that the expression of prostate-specific membrane antigen (PSMA) is restricted to endothelium from tumor-associated neovasculature. But the expression of PSMA in osteosarcoma and its clinical significance are unknown. Using immunohistochemical analysis and quantum dot probes, we found that 46.7% (21/45) of the osteosarcoma showed positive staining for PSMA while no PSMA staining in osteofibrous dysplasia. The expression and localization of PSMA was confirmed by CD34 staining. More importantly, the expression of PSMA is correlated with tumor size, pulmonary metastasis and worse survival (survival rate 63.2% in the PSMA-negative group versus 36.6% in the PSMA-positive group). Thus, PSMA could be used as an independent prognostic marker for the osteosarcoma patients, and PSMA staining in tumor-associated neovasculature may be a potential target for antineovasculature-based therapy in osteosarcoma.